Side-by-side · Research reference

CardiogenvsMT-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-MechanisticHUMAN-REVIEWED5/46 cited

BFDA-ApprovedHUMAN-REVIEWED9/51 cited

Cardiogen

Bioregulator · Cardiac

CardiacTissue target

Gene regulationMechanism

AnimalEvidence level

SQ · Variable protocols

MT-1

α-MSH Analogue · FDA-Approved

16 mgImplant dose

13 AAPeptide lengthChawathe 2026

2019FDA approval

SQ Implant · 60-Day Release

01Mechanism of Action

Parameter

Cardiogen

MT-1

Primary target

Cardiovascular cell gene expressionKhavinson 2022

Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010

Pathway

Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022

α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis

Downstream effect

Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue

Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010

Feedback intact?

Presumed — peptide bioregulators act via gene regulation, not receptor agonism

Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production

Origin

Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology

Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026

Antibody development

—

02Dosage Protocols

Parameter

Cardiogen

MT-1

Standard dose

Variable — typically 10–20 mg per course

No standardised human protocol; animal-derived dosing.

16 mg subcutaneous implant

FDA-approved formulation (Scenesse).

Frequency

Intermittent courses — 10–20 days, repeated periodically

Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.

Every 60 days

Sustained release implant — no daily administration required.

Evidence basis

Animal models / mechanistic studies

No Phase 1+ human trials in PubMed.

Phase 3 RCT / FDA-approved orphan drug

Route

Subcutaneous injection

Subcutaneous implant — upper arm or abdomen

Duration

10–20 day courses, repeated 2–4× per year

Russian geriatric protocols; unclear extrapolation to general populations.

Seasonal use (spring–autumn typical)

Aligned with peak UV exposure months.

Indication

—

Erythropoietic protoporphyria (EPP)

Narrow FDA approval — not licensed for cosmetic tanning.

Stability

—

Norleucine/D-Phe substitutions enhance peptidase resistance

Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).

04Side Effects & Safety

Parameter

Cardiogen

MT-1

Injection site reactions

Mild erythema, induration (presumed)

—

Systemic adverse events

No documented serious AEs in available literature

Very limited safety data; no rigorous pharmacovigilance.

—

Immunogenicity

Unknown — no antibody development studies published

—

Long-term safety

Unknown — no extended human trials indexed in PubMed

—

Nausea

—

Common (>10%) — mild, transient

Implant site reaction

—

Erythema, bruising, tenderness at insertion site

Hyperpigmentation

—

Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010 Habbema 2017

Expected melanogenic response — complicates pigmented lesion surveillance.

Melanocytic changes

—

Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017

Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.

Headache

—

Occasional (MC1R-independent melanocortin effects)

Photosensitivity (paradoxical)

—

Rare phototoxic reactions despite melanin increase

Contamination risk (unregulated)

—

Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010 Habbema 2017

Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.

Absolute Contraindications

Cardiogen

·Active malignancy (theoretical peptide growth factor concern)
·Hypersensitivity to peptide components

MT-1

·Hypersensitivity to afamelanotide or excipients
·Hepatic impairment (no safety data)
·Renal impairment (no safety data)

Relative Contraindications

Cardiogen

·Acute cardiac events (no safety data in acute MI, unstable angina)
·Pregnancy / lactation (no reproductive toxicity data)

MT-1

·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
·Pregnancy/lactation (insufficient data)
·Photosensitive dermatoses (other than EPP)

05Administration Protocol

Parameter

Cardiogen

MT-1

1. Reconstitution

Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.

Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.

2. Injection site

Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.

Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.

3. Timing

Variable — often evening injection. No established circadian preference.

Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.

4. Storage

Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.

New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.

5. Needle

27–30G insulin syringe, 45° angle for subcutaneous administration.

Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.

06Stack Synergy

Cardiogen

+ Thymalin

Moderate

View Thymalin →

Khavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.

Cardiogen: 10–20 mg SQ · 10–20 day course
Thymalin: 10–30 mg IM · concurrent or sequential courses
Frequency: 2–4 courses per year
Primary benefit: Multi-system aging mitigation, cardiovascular and immune homeostasis

MT-1

— no documented stacks